Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2014

01.05.2014

Periprocedural coagulability in patients undergoing ablation of atrial fibrillation: lessons from a periablation anticoagulation strategy of a brief withdrawal of warfarin without heparin bridging

verfasst von: Akinori Sairaku, Yukihiko Yoshida, Haruo Hirayama, Yukiko Nakano, Yasuki Kihara

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

We aimed to examine what becomes of the coagulable state when warfarin is interrupted in patients undergoing ablation of atrial fibrillation (AF). We studied 62 patients with a CHADS2 score of 0 or 1 who underwent ablation for paroxysmal AF. Warfarin was discontinued the day before the ablation without heparin-bridging, and intravenous heparin was administered during the procedure in a conventional manner, and warfarin was then resumed after achieving hemostasis of the access site. The international normalized ratio (INR) values or D-dimer levels were measured at five different time points during the periprocedural period, and the periprocedural hemorrhagic and thromboembolic complications were assessed. The INR value constantly decreased after withdrawal of warfarin, and did not recover to the level before its discontinuation at the time of hospital discharge despite a short interruption of warfarin (mean ± SD, 1.75 ± 0.52 to 1.41 ± 0.27, p < 0.0001). However, the D-dimer level continued to increase over a period of 48 h after the ablation in spite of the administration of a sufficient amount of heparin during the procedure and a quick resumption of warfarin (mean ± SD, 0.57 ± 0.19 to 0.85 ± 0.36 μg/mL, p < 0.0001). The INR value measured just before the ablation had a significant inverse correlation to the D-dimer levels assessed just before (r = −0.304), immediately after (r = −0.440), 24 h after (r = −0.442) and 48 h after the ablation (r = −0.463). In conclusion, the risk of hyper-coagulability may increase during the early postprocedural period of AF ablation in patients who were inappropriately anticoagulated with warfarin.
Literatur
1.
Zurück zum Zitat Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL et al (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e269–e367PubMedCrossRef Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL et al (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e269–e367PubMedCrossRef
2.
Zurück zum Zitat Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRef Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRef
3.
Zurück zum Zitat Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRef Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRef
4.
Zurück zum Zitat Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ et al (2012) 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 9(632–696):e21PubMed Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ et al (2012) 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 9(632–696):e21PubMed
5.
Zurück zum Zitat Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L et al (2007) Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation 116:2531–2534PubMedCrossRef Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L et al (2007) Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation 116:2531–2534PubMedCrossRef
6.
Zurück zum Zitat Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D et al (2010) Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 121:2550–2556PubMedCrossRef Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D et al (2010) Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 121:2550–2556PubMedCrossRef
7.
Zurück zum Zitat Kim JS, Jongnarangsin K, Latchamsetty R, Chugh A, Ghanbari H, Crawford T, Yokokawa M et al (2013) The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythm Electrophysiol 6:302–309PubMedCrossRef Kim JS, Jongnarangsin K, Latchamsetty R, Chugh A, Ghanbari H, Crawford T, Yokokawa M et al (2013) The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythm Electrophysiol 6:302–309PubMedCrossRef
8.
Zurück zum Zitat Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Inden Y et al (2013) A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 36:172–179PubMedCrossRef Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Inden Y et al (2013) A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 36:172–179PubMedCrossRef
9.
Zurück zum Zitat Genewein U, Haeberli A, Straub PW, Beer JH (1996) Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 92:479–485PubMedCrossRef Genewein U, Haeberli A, Straub PW, Beer JH (1996) Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 92:479–485PubMedCrossRef
10.
Zurück zum Zitat Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD, Beevers DG (1996) Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 94:425–431PubMedCrossRef Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD, Beevers DG (1996) Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 94:425–431PubMedCrossRef
11.
Zurück zum Zitat JCS Joint Working Group (2010) Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J 74:2479–2500CrossRef JCS Joint Working Group (2010) Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J 74:2479–2500CrossRef
12.
Zurück zum Zitat Ouyang F, Bänsch D, Ernst S, Schaumann A, Hachiya H, Chen M, Chun J et al (2004) Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 110:2090–2096PubMedCrossRef Ouyang F, Bänsch D, Ernst S, Schaumann A, Hachiya H, Chen M, Chun J et al (2004) Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 110:2090–2096PubMedCrossRef
13.
Zurück zum Zitat White RH, McKittrick T, Hutchinson R, Twitchell J (1995) Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 122:40–42PubMedCrossRef White RH, McKittrick T, Hutchinson R, Twitchell J (1995) Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 122:40–42PubMedCrossRef
14.
Zurück zum Zitat Palareti G, Legnani C (1996) Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 30:300–313PubMedCrossRef Palareti G, Legnani C (1996) Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 30:300–313PubMedCrossRef
15.
Zurück zum Zitat Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H, Hasegawa D et al (2007) Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 28:2217–2222PubMedCrossRef Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H, Hasegawa D et al (2007) Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 28:2217–2222PubMedCrossRef
16.
Zurück zum Zitat Sadanaga T, Sadanaga M, Ogawa S (2010) Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 55:2225–2231PubMedCrossRef Sadanaga T, Sadanaga M, Ogawa S (2010) Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 55:2225–2231PubMedCrossRef
17.
Zurück zum Zitat Lee DS, Dorian P, Downar E, Burns M, Yeo EL, Gold WL, Paquette M et al (2001) Thrombogenicity of radiofrequency ablation procedures: what factors influence thrombin generation? Europace 3:195–200PubMedCrossRef Lee DS, Dorian P, Downar E, Burns M, Yeo EL, Gold WL, Paquette M et al (2001) Thrombogenicity of radiofrequency ablation procedures: what factors influence thrombin generation? Europace 3:195–200PubMedCrossRef
18.
Zurück zum Zitat Bulava A, Slavík L, Fiala M, Heinc P, Skvarilova M, Lukl J, Krcová V et al (2004) Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins. J Interv Card Electrophysiol 10:271–279PubMedCrossRef Bulava A, Slavík L, Fiala M, Heinc P, Skvarilova M, Lukl J, Krcová V et al (2004) Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins. J Interv Card Electrophysiol 10:271–279PubMedCrossRef
19.
Zurück zum Zitat Wada H, Ikuma H, Mori Y, Shimura M, Hiyoyama K, Nakasaki T, Onoda K et al (2000) Increased hemostatic molecular markers in patients undergoing anticoagulant therapy. Semin Thromb Hemost 26:113–118PubMedCrossRef Wada H, Ikuma H, Mori Y, Shimura M, Hiyoyama K, Nakasaki T, Onoda K et al (2000) Increased hemostatic molecular markers in patients undergoing anticoagulant therapy. Semin Thromb Hemost 26:113–118PubMedCrossRef
20.
Zurück zum Zitat Sairaku A, Nakano Y, Oda N, Makita Y, Kajihara K, Tokuyama T, Kihara Y (2011) Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation. J Interv Card Electrophysiol 31:157–164PubMedCrossRef Sairaku A, Nakano Y, Oda N, Makita Y, Kajihara K, Tokuyama T, Kihara Y (2011) Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation. J Interv Card Electrophysiol 31:157–164PubMedCrossRef
21.
Zurück zum Zitat Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS et al (2013) Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 368:2084–2093PubMedCrossRef Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS et al (2013) Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 368:2084–2093PubMedCrossRef
22.
Zurück zum Zitat Hoke M, Koppensteiner R, Schillinger M, Haumer M, Minar E, Wiesbauer F, Huber CD et al (2010) D-dimer testing in the diagnosis of transfemoral pseudoaneurysm after percutaneous transluminal procedures. J Vasc Surg 52:383–387PubMedCrossRef Hoke M, Koppensteiner R, Schillinger M, Haumer M, Minar E, Wiesbauer F, Huber CD et al (2010) D-dimer testing in the diagnosis of transfemoral pseudoaneurysm after percutaneous transluminal procedures. J Vasc Surg 52:383–387PubMedCrossRef
Metadaten
Titel
Periprocedural coagulability in patients undergoing ablation of atrial fibrillation: lessons from a periablation anticoagulation strategy of a brief withdrawal of warfarin without heparin bridging
verfasst von
Akinori Sairaku
Yukihiko Yoshida
Haruo Hirayama
Yukiko Nakano
Yasuki Kihara
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2014
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-0982-0

Weitere Artikel der Ausgabe 4/2014

Journal of Thrombosis and Thrombolysis 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.